PolyMedix Presents New Data on Its Defensin-Mimetic Antibiotics at 52nd Annual ICAAC
September 11, 2012 16:15 ET
|
PolyMedix, Inc.
RADNOR, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious...
Data Showing Effectiveness of PolyCide Antimicrobial in Surgical Suture Coatings Published in American Chemical Society Journal, Langmuir
September 05, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Sept. 5, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious diseases,...
PolyMedix Antibiotic Studies Accepted for Presentation at ICAAC
August 21, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Aug. 21, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix Reports Second Quarter 2012 Financial Results
August 09, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Aug. 9, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix and University of Pennsylvania Collaborate to Develop New Class of Defensin-Mimetic Antimicrobial Compounds to Treat Malaria
July 31, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., July 31, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix Outlines Potential Benefits of GAIN Act to Its Antibiotic Development Program
July 13, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., July 13, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix Receives USAN Approval for Generic Name of Brilacidin for PMX-30063
June 12, 2012 16:30 ET
|
PolyMedix, Inc.
RADNOR, Pa., June 12, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
New Data on PMX-30063 Presented at ASCO Suggest Strong Potential as Treatment for Oral Mucositis
June 04, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., June 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix Provides Update on PMX-60056 Program
May 10, 2012 17:01 ET
|
PolyMedix, Inc.
RADNOR, Pa., May 10, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic
April 23, 2012 07:00 ET
|
PolyMedix, Inc.
Study in patients with Acute Bacterial Skin and Skin Structure Infections showed all three doses to have high clinical response rates and to be safe
Conference Call Today at 9:00 a.m....